Urinary Nucleosides as Biomarkers of Breast, Colon, Lung, and Gastric Cancer in Taiwanese

Wei-Yi Hsu1,2, Chao-Jung Chen1,3, Yu-Chuen Huang1,4, Fuu-Jen Tsai1,5, Long-Bin Jeng6, Chien-Chen Lai7,8*

1 Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, 2 China Medical University, Taichung, Taiwan, 3 Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan, 4 School of Chinese Medicine, China Medical University, Taichung, Taiwan, 5 Department of Health and Nutrition Biotechnology, Asia University, Taichung, Taiwan, 6 Department of Surgery, China Medical University Hospital, Taichung, Taiwan, 7 Institute of Molecular Biology, National Chung Hsing University, Taichung, Taiwan, 8 Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan

Abstract

Urinary nucleosides are associated with many types of cancer. In this study, six targeted urinary nucleosides, namely adenosine, cytidine, 3-methylcytidine, 1-methyladenosine, inosine, and 2-deoxyguanosine, were chosen to evaluate their role as biomarkers of four different types of cancer: lung cancer, gastric cancer, colon cancer, and breast cancer. Urine samples were purified using solid-phase extraction (SPE) and then analyzed using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The Mann-Whitney U test and Principal Component Analysis (PCA) were used to compare differences in urinary nucleosides between patients with one of four types of cancer and healthy controls. The diagnostic sensitivity of single nucleosides for different types of cancer ranged from 14% to 69%. In contrast, the diagnostic sensitivity of a set of six nucleosides ranged from 37% to 69%. The false-positive identification rate associated with the set of six nucleosides in urine was less than 2% compared with that of less than 5% for a single nucleoside. Furthermore, combining the set of six urinary nucleosides with carcinoembryonic antigen improved the diagnostic sensitivity for colon cancer. In summary, the study show that a set of six targeted nucleosides is a good diagnostic marker for breast and colon cancers but not for lung and gastric cancers.

Introduction

Davis et al. [1] were the first researchers to compare the concentration and ratio of urinary nucleosides between healthy individuals and patients with cancer. The nucleosides were isolated with a boronate affinity column and then separated using reversed-phase high-performance liquid chromatographic (HPLC)–ultraviolet (UV) methods. Since then, different technologies have been applied to identify and quantify target nucleosides or novel modified-nucleosides [2]. Sample preparation normally involves an extraction procedure to obtain well-purified and concentrated nucleosides from complex matrices in urine prior to instrumental analysis. Common pretreatment methods include solid phase extraction (SPE) with phenylboronic acid (PBA) as an extraction bed or gel for purification of vicinal hydroxyl groups involved in the structure of nucleosides [3,4], cation-exchange extraction for purification of positively charged nitrogen in nucleosides and deoxynucleosides [5], and C18 extraction for purification of hydrophobic moieties in nucleosides and deoxynucleosides [6,7]. Separation of urinary nucleosides is often carried out by chromatographic methods such as HPLC or Ultra Performance Liquid Chromatography (UPLC) [3,5,7,8] or electromigration techniques such as capillary electrophoresis [9,10]. The final stage involves the use of different types of detectors such as UV [10] or mass spectrometry (MS) [3,8]. It is well known that MS detection provides more molecular weight information (especially when tandem MS is used) and provides higher sensitivity and specificity than UV detection. Nowadays, separation techniques combined with MS are the most commonly used techniques for identification of novel nucleosides [7] and quantification of targeted nucleosides in urine.

Sowe et al. [11] demonstrated that 8-hydroxyguanosine was a good biomarker of breast cancer. Cho et al. [12] evaluated the accuracy and specificity of fourteen nucleosides for detecting breast cancer before and after tumor removal. In addition, Seidel et al. [13] reported that eighteen nucleosides could be used to predict at least nine different kinds of cancer. Furthermore, Woo et al. [6] found that a set of fourteen nucleosides could be used as a biomarker of breast, ovarian, and cervical cancer, and Szymanska et al. [10] reported that a set of nineteen nucleosides was predictive of bladder, prostate, kidney, and testicular cancer. In the present study, we investigated whether a set of six urinary nucleosides could serve as a universal biomarker of four different types of cancer in Taiwanese.
Materials and Methods

Chemicals and standard solutions

The nucleosides examined in this study were purchased from Sigma (St Louis, MO): cytidine, 3-methylcytidine, 1-methyladenosine, adenosine, inosine, 2’-deoxyguanosine, and tubercidin (internal standard, ISTD). HPLC-grade methanol and acetonitrile were purchased from LAB-SCAN Analytical Science (Labscan Ltd. Dublin, Ireland). Deionized water (Milli-Q water system, Millipore Inc., Bedford, MA) was used in the preparation of the samples and buffer solutions.

Stock solutions of the six nucleosides standards and the internal standard were prepared at concentrations ranging from 100–1000 µg/ml in methanol and kept in the dark at −20°C until used.

Instrumentation

The HPLC-ESI-MS/MS system consisted of a Surveyor™ HPLC system coupled with a Finnigan LCQ DECA XP™ quadrupole ion trap mass spectrometer. The separation of analytes was performed on a 3 µm C18 column (Atlantis@ dC18, 2.1 mm i.d.×100 mm, Waters). A guard column (Atlantis@ dC18, 2.1 mm i.d.×20 mm, Waters) was used to prolong the life of the HPLC column. The LCQ DECA XP™ MS system was equipped with a pneumatically-assisted electrospray ionization source and operated in positive ion mode by applying a voltage of 4 kV to the ESI needle. The temperature of the heated capillary in the ESI source was set at 295°C. The number of ions stored in the trap was set at 30 (arbitrary units).

Helium was used as the damping gas at a pressure of 10⁻³ Torr. Voltages across the capillary and the octopole lenses were tuned by an automated procedure to maximize signals of the ion of interest. In the MS/MS analysis, typical values for the relative collision energy (peak-to-peak amplitude of the resonance excitation) ranged from 0.4 to 0.8 eV. For quantitative experiments in SRM mode, the maximum ion collection time was 0.15 s for each step and each spectrum was scanned 3 times.

Collection of specimens

Urine samples from 149 subjects, including 26 with colon cancer, 36 with breast cancer, 27 with lung cancer, 15 with gastric cancer, and 45 healthy controls were collected at the China Medical University Hospital, Taichung, Taiwan. Patients with cancer had various stages of malignant disease and underwent different therapies (surgery, chemotherapy, radiotherapy). Cancer was graded using the TNM (Tumor-Node-Metastasis) classification system in all patients. The details of the patients with gastric or lung cancer are described in Table 1. Clinical characteristics of the patients with colon or breast cancer are described in our previous reports [5,14]. Urine samples were acidified using 2N HCl (adjusted to 0.01N HCl) and stored at −80°C in the dark until analysis. The study was approved by the ethical committee of the China Medical University Hospital. All participants have provided their written consent to participate in this study. The ethical committee of the China Medical University Hospital have approved this consent procedure

Sample preparation and HPLC-MS/MS analysis

Concentrations of nucleosides in urine were quantified by SPE with HPLC-MS/MS as reported previously [5,14]. Briefly, 1 ml of urine was added to 100 µl of internal standard (2 ug/mL) and subsequently passed through a 96-well cation-exchange cartridge (Oasis@ MCX column, Waters) to extract urinary nucleosides. The eluate from the SPE cartridge was then reconstituted in a

---

Table 1. Clinical characteristic of colon and lung cancer patients.

| Patient no. | Sex | Age | TMN Stage | Cell type          |
|-------------|-----|-----|-----------|--------------------|
| 1. Gastric cancer patients |
| G2          | M   | 61  | T3 N0 M0  | Stage II           | adenocarcinoma     |
| G4          | M   | 69  | T3 N2 M0  | Stage IIB         | adenocarcinoma     |
| G6          | M   | 78  | T3 N1 M0  | Stage IIIA        | adenocarcinoma     |
| G7          | M   | 65  | Tx Nx M1  | Stage IV           | adenocarcinoma     |
| G8          | M   | 73  | T3 N2 M0  | Stage IIIb        | adenocarcinoma     |
| G9          | F   | 56  | T4a Nx M1 | Stage IV           | adenocarcinoma     |
| G10         | F   | 82  | T4b Nx Mx | Stage x            | adenocarcinoma     |
| G11         | M   | 65  | T2a N2 M0 | Stage IIIA         | adenocarcinoma     |
| G14         | M   | 53  | T3 N0 M2  | Stage II           | adenocarcinoma     |
| G16         | M   | 59  | T2 N1 M0  | Stage II           | adenocarcinoma     |
| G17         | M   | 50  | T1 N0 M0  | Stage IA          | adenocarcinoma     |
| G20         | M   | 82  | T3 N0 M2  | Stage II           | adenocarcinoma     |
| G21         | F   | 78  | T1 N0 M0  | Stage IA          | adenocarcinoma     |
| G27         | M   | 54  | T4 N2 M0  | Stage IV           | adenocarcinoma     |
| G28         | M   | 81  | Tx Nx M1  | Stage IV           | adenocarcinoma     |
| 2. Lung cancer patients |
| L1          | M   | 74  | T4 N0 Mx  | Stage IIIB        | squamous cell      |
| L2          | M   | 73  | T3 N2 M1  | Stage IV           | squamous cell      |
| L3          | M   | 71  | limited disease | small cell   |                    |
| L4          | F   | 56  | T2 N0 M0  | Stage IB          | adenocarcinoma     |
| L5          | M   | 56  | T4 N2 Mx  | Stage IIIB        | adenocarcinoma     |
| L6          | F   | 58  | T2 N3 M1  | Stage IV           | adenocarcinoma     |
| L7          | M   | 68  | T4 N3 Mx  | Stage IIIB        | adenocarcinoma     |
| L8          | F   | 61  | T2 Nx M1  | Stage IV           | adenocarcinoma     |
| L9          | M   | 72  | T4 N3 Mx  | Stage IIIB        | adenocarcinoma     |
| L10         | F   | 55  | T4 N2 M1  | Stage IV           | small cell         |
| L12         | M   | 49  | T4 N1 M0  | Stage IIIB        | squamous cell      |
| L13         | F   | 43  | T1 N2 M1  | Stage IV           | adenocarcinoma     |
| L14         | M   | 66  | T3 N2 M1  | Stage IV           | adenocarcinoma     |
| L15         | F   | 54  | T2 N1 M0  | Stage IV           | squamous cell      |
| L16         | M   | 64  | T2 Nx M1  | Stage IV           | adenocarcinoma     |
| L17         | M   | 60  | T1 N3 M1  | Stage IV           | adenocarcinoma     |
| L18         | M   | 50  | T2 N3 M1  | Stage IV           | adenocarcinoma     |
| L20         | F   | 46  | T3 N2 M1  | Stage IV           | adeno-squamous cell|
| L21         | M   | 81  | T4 N2 M0  | Stage IIIB        | squamous cell      |
| L22         | M   | 68  | T4 N3 Mx  | Stage IIIB        | squamous cell      |
| L23         | M   | 65  | T2 N2 M1  | Stage IV           | adenocarcinoma     |
| L24         | F   | 67  | T4 Nx M1  | Stage IV           | adenocarcinoma     |
| L25         | F   | 66  | Stage IV  |                | adenocarcinoma     |
| L26         | F   | 64  | T2 N0 M0  | Stage IIIB        | adenocarcinoma     |
| L29         | M   | 70  | T2 N3 M1  | Stage IV           | adenocarcinoma     |
| L30         | F   | 42  | T2 N3 M1  | Stage IV           | adenocarcinoma     |
| L31         | M   | 42  | T2 N2 M1  | Stage IV           | squamous cell      |

doi:10.1371/journal.pone.0081701.t001
100 μl solution of the mobile phase (2 mmol/l aqueous ammonium acetate, pH 5.0). The concentrated urine (2 μl) was then injected into the HPLC system for analysis. The mobile phases of HPLC system were (A) 2 mmol/l aqueous ammonium acetate (pH 5.0) and (B) 50% methanolic 2 mmol/l ammonium acetate. The flow rate was 0.2 ml/min. The gradient conditions were as follows: isocratic elution (95% A) for 5 min, followed by a 2 min gradient to 20% B, then a gradient to 30% B in 3 min, then the final gradient to 40% B in 10 min. Typically, the analysis lasted 20 min and an additional 15 min was required to re-equilibrate the column. Front eluent (retention time <3 min) was diverted to waste rather than the mass spectrometer to avoid the ionic and polar components, thus minimizing contamination of the electrospray source.

The MS/MS experiment with SRM transitions was set for the quantification of nucleosides as follows: cytidine, m/z 244→112; 3-methylcytidine, m/z 258→126; 1-methyladenosine, m/z 282→150; adenosine, m/z 268→136; inosine, m/z 269→137; 2'-deoxyguanosine, m/z 268→152 and tubercidin, m/z 267→135. To compensate for variations in urine concentration, all nucleoside concentrations were indexed against creatinine and expressed as nmol nucleoside/mmol creatinine. The urinary

### Table 2. Variation of individual nucleosides levels in the urine samples from normal controls and cancer patients.

| Nucleosides          | Normal controls (n = 45) | All cancer patients (n = 104) | p-Value | Fold change |
|----------------------|--------------------------|------------------------------|---------|-------------|
|                      | Ave±SD | Median | Range | Ave±SD | Median | Range |          |            |
| Cytidine             | 1.25±0.83 | 0.96   | 0.28–4.17 | 2.29±1.78 | 1.90   | 0.14–8.8 | 0.00     | 1.9         |
| 3-methylcytidine     | 0.81±0.27 | 0.76   | 0.28–1.38 | 1.19±0.8 | 1.07   | 0.22–5.88 | 0.01     | 1.5         |
| 1-methyladenosine    | 6.47±2.47 | 6.59   | 2.47–13.14 | 9.16±5.19 | 8.42   | 1.22–26.28 | 0.00     | 1.4         |
| 2-deoxyguanosine     | 0.15±0.13 | 0.09   | 0.03–0.55 | 0.22±0.24 | 0.13   | 0.02–1.18 | 0.41     | 1.7         |
| Adenosine            | 2.07±0.87 | 1.8    | 0.75–4.11 | 3.88±2.62 | 3.31   | 0.3–15.23 | 0.00     | 1.9         |
| Inosine              | 0.3±0.32 | 0.21   | 0.03–1.88 | 0.64±0.77 | 0.35   | 0.04–5.02 | 0.00     | 2.0         |

Fold change calculated by average.
p-Value: Mann-Whitney U test.
doi:10.1371/journal.pone.0081701.t002
creatinine levels were determined by a modified Jaffe method whose principle is the reaction between creatinine and picric acid using colorimetric detection. [15]

Statistical analyses
Alterations between the nucleosides obtained for different groups (total cancer patients versus normal controls and individual cancer patients versus normal controls) were evaluated by the Mann-Whitney U test. Breast cancer patients were compared with healthy females. Principal Component Analysis (PCA) was used to recognize patterns and was also applied to check the dataset structure and assess the variability of the profiles belonging to groups of total cancer patients versus normal controls and individual cancer patients versus normal controls. The relationships between urinary nucleosides levels and tumor stages of individual cancer groups were analyzed by Spearman’s correlation test. All statistical analyses were performed with the statistical package SPSS for Windows (Version 17, SPSS, Chicago, IL, USA).

Results and Discussion
HPLC-ESI-MS/MS
In this study, an HPLC-ESI-MS/MS method was used to identify and quantify urinary nucleosides. Chromatographic retention time and specific mass information (both parent ion and daughter ion) of nucleosides were used to confirm with those of their relative standards. MS/MS (SRM transition was used in this study) detected molecular mass and structural information, allowing greater accuracy at identifying compounds than traditional UV detection. In other words, the coexisting eluents from Table 3. Variation of individual nucleosides levels in the urine samples from female and male normal controls.

| Nucleosides     | Female (n = 25) | Median | Range | p-Value | Fold change* | Male (n = 20) | Median | Range | p-Value | Fold change* |
|-----------------|----------------|--------|-------|---------|-------------|--------------|--------|-------|---------|-------------|
| Cytidine        | 1.54±0.92      | 1.31   | 0.28–4.17 | 0.88±0.52 | 0.72 | 0.32–2.49 | 0.00 |
| 3-methylcytidine| 0.86±0.27      | 0.81   | 0.5–1.38 | 0.75±0.27 | 0.70 | 0.28–1.34 | 0.21 |
| 1-methyladenosine| 7.41±2.59   | 7.34   | 2.93–13.14 | 5.28±1.73 | 5.37 | 2.47–8.12 | 0.01 |
| 2-deoxyguanosine| 0.19±0.17      | 0.15   | 0.03–0.55 | 0.11±0.07 | 0.08 | 0.03–0.23 | 0.39 |
| Adenosine       | 2.43±0.9       | 2.55   | 0.92–4.11 | 1.61±0.57 | 1.50 | 0.75–3.18 | 0.00 |
| Inosine         | 0.32±0.22      | 0.28   | 0.06–0.9 | 0.27±0.42 | 0.16 | 0.03–1.88 | 0.02 |

*p-Value: Mann-Whitney U test.
doi:10.1371/journal.pone.0081701.t003

Table 4. Variation of individual nucleosides levels in the urine samples from breast, lung, gastric and colon cancer patients.

| Nucleosides     | Breast cancer (n = 36) | Median | Range | p-Value* | Fold change* | Lung cancer (n = 27) | Median | Range | p-Value** | Fold change** |
|-----------------|------------------------|--------|-------|----------|-------------|----------------------|--------|-------|-----------|--------------|
| Cytidine        | 3.01±2.18              | 2.49   | 0.14–8.8 | 0.00     | 1.95 | 1.59±1.15 | 1.43 | 0.28–5.99 | 0.17 | 1.27 |
| 3-methylcytidine| 1.57±0.74              | 1.56   | 0.3–3.18 | 0.00     | 1.81 | 0.97±0.38 | 0.9  | 0.45–1.66 | 0.11 | 1.20 |
| 1-methyladenosine| 9.37±5.06             | 9.09   | 1.22–19.12 | 0.21     | 1.26 | 7.49±2.76 | 7.45 | 3.42–14.04 | 0.16 | 1.16 |
| 2-deoxyguanosine| 0.24±0.18              | 0.16   | 0.08–0.75 | 0.33     | 1.31 | 0.32±0.34 | 0.15 | 0.03–1.18 | 0.11 | 2.13 |
| Adenosine       | 3.34±1.84              | 3.20   | 0.3–7.38 | 0.13     | 1.37 | 2.84±1.39 | 2.62 | 1.05–5.68 | 0.02 | 1.38 |
| Inosine         | 0.94±0.74              | 0.82   | 0.11–3.36 | 0.00     | 2.90 | 0.36±0.3 | 0.29 | 0.04–1.06 | 0.38 | 1.20 |

| Nucleosides     | Gastric cancer (n = 15) | Median | Range | p-Value** | Fold change** | Colon cancer (n = 26) | Median | Range | p-Value** | Fold change** |
|-----------------|-------------------------|--------|-------|-----------|--------------|----------------------|--------|-------|-----------|--------------|
| Cytidine        | 2.18±1.79               | 1.89   | 0.29–6.69 | 0.07     | 1.75 | 2.08±1.35 | 1.80 | 0.5–7.57 | 0.00 | 1.67 |
| 3-methylcytidine| 1.26±1.4                | 1.00   | 0.3–5.88 | 0.40     | 1.54 | 0.86±0.55 | 0.64 | 0.22–2.56 | 0.55 | 1.05 |
| 1-methyladenosine| 10.77±7.65            | 9.14   | 2.6–26.28 | 0.05     | 1.67 | 9.71±5.42 | 8.80 | 1.8–24.17 | 0.01 | 1.50 |
| 2-deoxyguanosine| 0.12±0.11               | 0.07   | 0.04–0.35 | 0.45     | 0.78 | 0.15±0.19 | 0.08 | 0.02–0.81 | 0.45 | 1.00 |
| Adenosine       | 3.41±2.51               | 2.74   | 0.57–9.2 | 0.15     | 1.65 | 5.97±3.4  | 5.37 | 0.76–15.23 | 0.00 | 2.89 |
| Inosine         | 0.96±1.43               | 0.37   | 0.06–5.02 | 0.10     | 3.28 | 0.3±0.33 | 0.19 | 0.06–1.21 | 0.78 | 1.00 |

*Compared with “female normal controls”.
**Compared with “total normal controls”.
Fold change calculated by average.
p-Value: Mann-Whitney U test.
doi:10.1371/journal.pone.0081701.t004
HPLC were separated by MS detection if they had different molecular mass patterns. As seen in Fig. 1, adequate chromatographic separation of the six urinary nucleosides for the pooled cancer patients was achieved. The insets show the SRM transition spectra of each nucleoside. The parent ion, protonated nucleoside [M+H]⁺ was the most abundant ion. After collision-induced dissociation, the daughter ion, protonated base moiety [BH2]⁺, was analyzed with mass spectrometry. This protonated base moiety was a product of the breakdown of the glycosidic bond from the loss of a ribose moiety [MH-132]⁺ (for cytidine, 3-methylcytidine, 1-methyladenosine, adenosine, inosine, tubercidine) or 2'-deoxyribose moiety [MH-116]⁺ (for 2'-deoxyguanosine). The methods used to determine accuracy, precision, linearity, and recovery were similar to those described previously [5,14].

Levels of urinary nucleosides

Concentrations of the six nucleosides in urine from 149 subjects were quantified by the HPLC-MS/MS method as described above. The concentrations were normalized against urinary creatinine and expressed as nmol nucleoside/μmol creatinine. The results were analyzed by the Mann-Whitney U test to compare differences in level of each nucleoside between different groups. As shown in Table 2, average values, standard deviation, median values and range of nucleoside levels were elevated in all cancer patients in comparison to total normal controls (about 1.2 fold change). Significant differences (p<0.01) were found for five of the six nucleosides, namely cytidine, 3-methylcytidine, 1-methyladenosine, adenosine, inosine and tubercidine between the two groups. We also assessed the different nucleosides levels between female and male normal controls (Table 3). Higher levels of the six nucleosides were expressed in female in comparison to male normal controls. Four nucleosides, namely cytidine, 1-methyladenosine, adenosine and inosine were significantly different between the two groups. Similar results were observed in Struck’s study [3].

Next we evaluated the variation in urinary nucleosides between different types of cancer and normal controls. The group of breast cancer patients was compared with female normal controls only. We found that different sets of nucleosides were significantly associated with different types of cancer (Table 4). For example, cytidine, 3-methylcytidine, and inosine were significantly elevated in breast cancer patients; and cytidine, 1-methyladenosine, and adenosine were significantly elevated in colon cancer patients. Adenosine was the only nucleoside that was significantly elevated in urine from patients with lung cancer. However, there was no nucleoside significantly elevated in urine from patients with gastric cancer (p>0.05). Subsequently, cross-comparison between different cancer groups was further examined. Data (Table S1) showed that adenosine level in colon cancer group was significantly different from lung, gastric and breast cancer groups. Nucleosides levels were no significantly different between gastric and lung cancer. However, urinary nucleosides levels in breast cancer, a hormone-dependent cancer were more variable when comparing with other non hormone-dependent cancers (female only). The variable pattern of nucleosides in patients with various kinds of cancer may be due to the heterogeneity of different cancers. Studies have shown that nucleosides in urine are commonly elevated in cancer patients because of the increased tRNA methyltransferase activity or tRNA turn-over rate and that the elevated level of nucleosides excreted in urine is associated with kinetic growth parameters of different cancers,[16,17] Besides, we also examined the relationship of urinary nucleosides levels from individual cancers with each tumor stages by Spearman’s rho correlation test. Data (Table S-2) showed that adenosine levels were moderate to good correlate to tumor stages in lung cancer patients (Spearman’s rho =0.59, p<0.05). However, no other
significant correlation was observed in other three kinds of cancer groups.

The profiles of nucleosides in urine from cancer patients and normal controls were explored by PCA to assess the strength of the relationship between nucleoside profiles and cancer. Additionally, the extracted PCA factors were used to examine the ability to discriminate between cancer patients and normal controls. PCA showed that the total variance of patients and controls explained by the first PCA (PCA 1) was 51% whereas the second PCA (PCA 2) explained nearly 17% of the variance. PCA 1 was affected mostly by metabolites 1-methyladenosine (0.87) and 3-methylcytidine (0.84) and PCA 2 was influenced mostly by 2-deoxyguanosine (0.69). The PCA 1/PCA 2 score plots revealed that the samples from normal controls were more homogeneous than those from patients with cancer (Fig. 2A). The result was consistent with previous reports that PCA analysis of cancer patients were more dispersed, which were associated with their high diversity in tumor stage and cancer type.[3] Furthermore, as seen in Fig. 2B–E, we obtained a clear separation between normal controls and individual cancer groups.

Comparison of diagnostic sensitivity of a single nucleoside and a set of six nucleosides

On the basis of average values obtained from the normal controls, a cut-off value was defined as average plus 2-fold standard deviation for each nucleoside to decrease the false-positive identification rate of normal controls to less than 5%. This was also related to a specificity greater than 95%, which was defined as correctly classified normal controls in previous reports [3,18]. The percentage of each cancer group with a urinary nucleoside (significantly variation, p < 0.01) level above the cut-off value was calculated and used to define diagnostic sensitivity. In the group of gastric cancer, 1-methyladenosine (p = 0.052) was chosen as candidate nucleoside marker. Breast cancer patients

![Figure 3. Diagnostic sensitivity and false-positive identify for cancers provided by a single nucleoside and the set of six nucleosides. (A) All cancer; (B) Colon cancer; (C) Breast cancer; (D) Lung cancer and (E) Gastric cancer. doi:10.1371/journal.pone.0081701.g003](image1)

![Figure 4. Diagnostic sensitivity for colon cancers provided by combination of serum carcinoembryonic antigen (CEA) > 5 ng/ul with urinary (A) adenosine or (B) set of six nucleosides. doi:10.1371/journal.pone.0081701.g004](image2)
were compared with female normal controls. A set of six nucleosides was also defined as a diagnostic marker by the result of PCA analysis, and a dotted line was used as a boundary to separate the normal control group from the cancer groups. The percentage of cancer patients on one side of the boundary was calculated and used to define diagnostic sensitivity. Also, the false-positive identification rate of normal controls was calculated as the percentage of normal controls on same side of the boundary. The specific line across the PCA scatter plot was selected to obtain the maximal value of sensitivity and minimal value of false-positive.

Fig. 3 shows the diagnostic sensitivity (white box) of the methods for detecting each type of cancer and the false-positive (black box) rate in the normal controls. Also, we compared the diagnostic strengths provided by a single nucleoside with those provided by the set of six nucleosides. In the “all cancer” group, the diagnostic sensitivities ranged from 19% to 41% for the single nucleoside. The diagnostic sensitivity of the set of six nucleosides was, however, approximately 50% (50 of 104 patients). In the colon cancer group, the diagnostic sensitivity was 69% (18 of 26 patients) for the single nucleoside (adenosine) and for the set of six nucleosides. The false-positive identification rate decreased from 5% to 2% when the set of six nucleosides was used. In the other three groups, the set of six nucleosides provided a higher diagnostic sensitivity of 64% (23 of 36 patients) for breast cancer; 37% (10 of 27 patients) for lung cancer and 40% (6 of 15) for gastric cancer than single nucleoside marker. The false identification rate decreased from 5% to 2% (for lung cancer) and to 1% (for gastric cancer) when calculated using the set of six nucleosides.

Next, we combined the urinary nucleoside values with the value of serum carcinoembryonic antigen (CEA) from patients with colon cancer to improve the diagnostic sensitivity (Fig. 4). Serum CEA is a routine diagnostic marker for colon cancer in our hospital. Of the 26 colon cancer patients, cancer cannot be detected using the set of six urinary nucleosides and 4 patients had higher serum CEA levels (cut-off value of 5 ng/ml). Therefore, the diagnostic sensitivity of the method at detecting colon cancer increased from 68 to 83% (4+18 of 26 patients). In the same way, combination of the urinary nucleoside adenosine and serum CEA improved the diagnostic sensitivity of the method at detecting colon cancer from 68% to 81% (3+18 of 26 patients). The results show that integration of urinary nucleosides with routine markers elevates the diagnostic sensitivity of detecting cancer.

The set of six nucleosides was a good diagnostic marker for breast and colon cancer (diagnostic sensitivity >60%, false-positive identification <2%), but not for lung and gastric cancer (diagnostic sensitivity <40%). Few studies have evaluated the relationship between urinary nucleosides and lung or gastric cancer. McEntire et al [18] reported that serum nucleosides, other than urinary nucleosides, had a sensitivity of 84% and a specificity of 79% for detecting lung cancer. They reported that serum nucleosides may be subjected to fewer structural alternations than urinary nucleosides and may account for higher serum levels of some nucleosides.

Conclusion

We used a well-established SPE-HPLC-MS/MS method to quantify urinary nucleosides. The MS-based method was analytically sensitive and specific and was capable of analyzing multiple nucleosides in a single run of HPLC. Our results show that a set of nucleosides is a good diagnostic marker of cancer and that diagnostic sensitivity can be improved by comparing urinary nucleoside levels with those of well-known serum biomarkers, like serum CEA. In this study, the set of six nucleosides was not sensitive at detecting lung and gastric cancer. It is, therefore, necessary to consider different nucleosides for different kinds of cancer.

Supporting Information

Table S1 Variation of individual nucleoside levels in the urine samples between lung, colon, gastric and breast cancer patients. (DOC)

Table S2 S Spearman’s rho correlation coefficients between individual nucleosides levels and tumor stages (0 to IV) in each cancer patients. (DOC)

Author Contributions

Conceived and designed the experiments: FJT LBJ CCL. performed the experiments: WYH. Analyzed the data: WYH. Contributed reagents/materials/analysis tools: CJC FJT LBJ. Wrote the paper: WYH CCL. Contributed statistical analysis: YCH.

References

1. Davis GE, Suits RD, Kuo KC, Gehrke CW, Waalkes TP, et al. (1977) High-performance liquid chromatographic separation and quantitation of nucleosides in urine and some other biological fluids. Clin chim acta 23: 1427–1435.
2. Struck W, Wazszczuk-Jankowska M, Kaliszczan R, Markuszweski MJ (2011) The state-of-the-art determination of urinary nucleosides using chromatographic techniques ”hyphenated” with advanced bioinformatic methods. Anal Bioanal Chem 401: 2039-2050.
3. Struck W, Siluk D, Yumba-Mpanga A, Markuszweski M, Kaliszczan R, et al. (2013) Liquid chromatography tandem mass spectrometry study of urinary nucleosides as potential cancer markers. J Chromatogr A 1283: 122–131.
4. Gehrke CW, Kuo KC, Davis GE, Suits RD, Waalkes TP, et al. (1978) Quantitative high-performance liquid chromatography of nucleosides in biological materials. J Chromatogr 150: 455–476.
5. Hsu W-Y, Chen WT-L, Liu W-D, Tsai F-J, Tsai Y, et al. (2009) Analysis of urinary nucleosides as potential tumor markers in human colorectal cancer by high performance liquid chromatography/electrospray ionization tandem mass spectrometry. Clin Chim Acta 402: 31–37.
6. Woo HM, Kim KM, Choi MH, Jung BH, Lee J, et al. (2009) Mass spectrometry based metabolomic approaches in urinary biomarker study of women’s cancers. Clin Chim Acta 400: 63–69.
7. Li HY, Wang SM, Liu HM, Bu SS, Li J, et al. (2009) Separation and identification of purine nucleosides in the urine of patients with malignant cancer by reverse phase liquid chromatography/electrospray tandem mass spectrometry. J Mass Spectrom 44: 641–651.
8. Rodriguez-Gonzalo E, Garcia-Gomez D, Carabias-Martinez R (2011) Development and validation of a hydrophilic interaction chromatography-tandem mass spectrometry method with on-line polar extraction for the analysis of urinary nucleosides. Potential application in clinical diagnosis. J Chromatogr A 1218: 9055–9063.
9. Markuszweski MJ, Struck W, Wazszczuk-Jankowska M, Kaliszczan R (2010) Metabolomic approach for determination of urinary nucleosides as potential tumor markers using electrophoresis techniques. Electrophoresis 31: 2300–2310.
10. Szynszka E, Markuszweski MJ, Markuszweski M, Kaliszczan R (2010) Altered levels of nucleoside metabolite profiles in urogenital tract cancer measured by capillary electrophoresis. J Pharm Biomed Anal 53: 1303–1312.
11. Soylu H, Jakkoila-Vuorenien A, Paitola U, Kaupila S, Karhula P (2010) β-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer. Br J Cancer 102: 1018–1023.
12. Cho SH, Choe MH, Lee WW, Chung BC (2009) Evaluation of urinary nucleosides in breast cancer patients before and after tumor removal. Clin Biochem 42: 540–543.
13. Seidel A, Brunner S, Seidel P, Fritz GI, Herbarth O (2006) Modified biological materials/analysis tools: CJC FJT LBJ. Wrote the paper: WYH CCL. Contributed statistical analysis: YCH.
15. Bartels H, Bohmer M, Heierli C (1972) Serum creatinine determination without protein precipitation. Clin Chim Acta 37: 193–197.

16. Borek E (1971) Transfer RNA and transfer RNA modification in differentiation and neoplasia. Introduction. Cancer Res 31: 596–597.

17. Borek E, Baliga BS, Gehrke CW, Kuo CW, Belman S, et al. (1977) High turnover rate of transfer RNA in tumor tissue. Cancer Res 37: 3362–3366.

18. McEntire JE, Kuo KC, Smith ME, Stalling DL, Richens JW, et al. (1989) Classification of lung cancer patients and controls by chromatography of modified nucleosides in serum. Cancer Research 49: 1057–1062.